The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results